Carl June
Cited by
Cited by
Chimeric antigen receptor T cells for sustained remissions in leukemia
SL Maude, N Frey, PA Shaw, R Aplenc, DM Barrett, NJ Bunin, A Chew, ...
New England Journal of Medicine 371 (16), 1507-1517, 2014
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, ...
New England Journal of Medicine 378 (5), 439-448, 2018
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
DL Porter, BL Levine, M Kalos, A Bagg, CH June
New England Journal of Medicine 365 (8), 725-733, 2011
Chimeric antigen receptor–modified T cells for acute lymphoid leukemia
SA Grupp, M Kalos, D Barrett, R Aplenc, DL Porter, SR Rheingold, ...
New England Journal of Medicine 368 (16), 1509-1518, 2013
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
M Kalos, BL Levine, DL Porter, S Katz, SA Grupp, A Bagg, CH June
Science translational medicine 3 (95), 95ra73-95ra73, 2011
Cytokine storm
DC Fajgenbaum, CH June
New England Journal of Medicine 383 (23), 2255-2273, 2020
CAR T cell immunotherapy for human cancer
CH June, RS O’Connor, OU Kawalekar, S Ghassemi, MC Milone
Science 359 (6382), 1361-1365, 2018
Cytokine release syndrome in severe COVID-19
JB Moore, CH June
Science 368 (6490), 473-474, 2020
A human memory T cell subset with stem cell–like properties
L Gattinoni, E Lugli, Y Ji, Z Pos, CM Paulos, MF Quigley, JR Almeida, ...
Nature medicine 17 (10), 1290-1297, 2011
Delivery technologies for cancer immunotherapy
RS Riley, CH June, R Langer, MJ Mitchell
Nature reviews Drug discovery 18 (3), 175-196, 2019
Chimeric antigen receptor therapy
CH June, M Sadelain
New England Journal of Medicine 379 (1), 64-73, 2018
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
DL Porter, WT Hwang, NV Frey, SF Lacey, PA Shaw, AW Loren, A Bagg, ...
Science translational medicine 7 (303), 303ra139-303ra139, 2015
The B7 and CD28 receptor families
CH June, JA Bluestone, LM Nadler, CB Thompson
Immunology today 15 (7), 321-331, 1994
Chimeric antigen receptor T cells in refractory B-cell lymphomas
SJ Schuster, J Svoboda, EA Chong, SD Nasta, AR Mato, Anak, ...
New England Journal of Medicine 377 (26), 2545-2554, 2017
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV
P Tebas, D Stein, WW Tang, I Frank, SQ Wang, G Lee, SK Spratt, ...
New England Journal of Medicine 370 (10), 901-910, 2014
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL
LH Boise, AJ Minn, PJ Noel, CH June, MA Accavitti, T Lindsten, ...
Immunity 3 (1), 87-98, 1995
The CD28 signaling pathway regulates glucose metabolism
KA Frauwirth, JL Riley, MH Harris, RV Parry, JC Rathmell, DR Plas, ...
Immunity 16 (6), 769-777, 2002
Regulatory CD4+ CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer
EY Woo, CS Chu, TJ Goletz, K Schlienger, H Yeh, G Coukos, SC Rubin, ...
Cancer research 61 (12), 4766-4772, 2001
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T…
JM Chemnitz, RV Parry, KE Nichols, CH June, JL Riley
The Journal of Immunology 173 (2), 945-954, 2004
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
DM O’Rourke, MLP Nasrallah, A Desai, JJ Melenhorst, K Mansfield, ...
Science translational medicine 9 (399), eaaa0984, 2017
The system can't perform the operation now. Try again later.
Articles 1–20